HEALTH CARE:
PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Immunomedics Inc. develops, manufactures and markets monoclonal antibody-based products for detection and treatment of cancer and other diseases. Focuses on therapeutic antibodies designed to carry radioisotopes, chemotherapeutic agents, toxins and other substances to a specific disease site or organ system.
Market Cap | 20.24 Billion | Shares Outstanding | 231.157 Million | Avg 30-day Volume | 7.47 Million |
P/E Ratio | Dividend Yield | EPS | -1.73 | ||
Price/Sales | 993.671 | Price cash flow ratio | 57.4 | Price free cash flow ratio | -102.7 |
Book Value | 2.57 | Price to Tangible Book | 34.09 | Alpha | 0.07 |
Short Interest Ratio | % Short Interest to Float | R-squared | 0.186713 | ||
BETA | 2.90081 | 52-week High/Low | 87.64 / 8.8 | Stddev | 0.288309 |
Q3 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 61 | 15 | 306.67% | 46 (3.02%) | 11 (0.71%) | 318.18% |
Funds Holding: | 397 | 311 | 27.65% | 140 (9.2%) | 103 (6.68%) | 35.92% |
13F shares: | 193.53 Million | 205.427 Million | -5.79% | 106.255 Million | 90.346 Million | 17.61% |
% Ownership | 83.7224 | 88.874 | -5.8% | 45.9668 | 39.0864 | 17.6% |
New Positions: | 154 | 117 | 31.62% | 66 | 46 | 43.48% |
Increased Positions | 85 | 89 | -4.49% | 30 | 26 | 15.38% |
Closed Positions | 63 | 22 | 186.36% | 29 | 6 | 383.33% |
Reduced Positions | 130 | 81 | 60.49% | 38 | 25 | 52.0% |
Total Calls | 5.04 Million | 4.957 Million | 1.66% | 1.436 Million | 1.009 Million | 42.33% |
Total Puts | 3.642 Million | 1.781 Million | 104.44% | 2.365 Million | 730 Thousand | 223.97% |
PUT/CALL Ratio | 0.72 | 0.36 | 100.0% | 1.65 | 0.72 | 129.17% |
Heat Map Ranking | 42 | |||||
Heat Map Ranking | 29 | |||||
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2020-10-23 | 2 | |
|
0 | 2020-10-23 | 2 | |
|
0 | 2020-10-23 | 2 | |
|
0 | 2020-10-23 | 2 | |
DELANEY BRENDAN CHIEF COMMERCIAL OFFICER |
|
0 | 2020-10-23 | 2 |
MALIK USAMA CHIEF FIN. & BUSINESS OFFICER |
|
0 | 2020-10-23 | 2 |
FRICKER WILLIAM PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2020-10-23 | 1 |
FREEDBERG JARED GEN. COUNSEL & CORP. SECRETARY |
|
0 | 2020-10-23 | 2 |
ANDREWS KURT J. CHIEF HUMAN RESOURCES OFFICER |
|
0 | 2020-10-23 | 2 |
|
0 | 2020-10-23 | 2 | |
|
0 | 2020-10-23 | 5 | |
BALL BRYAN CHIEF QUALITY OFFICER |
|
0 | 2020-10-23 | 2 |
ITRI LORETTTA M CHIEF MEDICAL OFFICER |
|
0 | 2020-10-23 | 3 |
|
0 | 2020-10-23 | 4 | |
SEMERJIAN HAROUT PRESIDENT AND CEO |
|
0 | 2020-04-16 | 2 |
ROSENBERG MORRIS CHIEF TECHNOLOGY OFFICER |
|
0 | 2019-09-06 | 0 |
IANNONE ROBERT CHIEF MEDICAL OFFICER |
|
0 | 2019-03-14 | 0 |
PEHL MICHAEL F. PRESIDENT AND CEO |
|
0 | 2018-09-14 | 0 |
|
7,387,537 | 2018-02-28 | 0 | |
|
90,788 | 2017-11-20 | 0 | |
|
16,064,461 | 2017-11-14 | 2 | |
|
16,064,461 | 2017-11-14 | 2 | |
|
5,906,233 | 2017-08-31 | 0 | |
GARONE MICHAEL CHIEF FINANCIAL OFFICER |
|
0 | 2017-07-03 | 0 |
|
No longer subject to file | 2017-06-30 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
78,325 | 2016-12-02 | 0 | |
|
0 | 2015-12-02 | 0 | |
|
No longer subject to file | 2015-12-01 | 0 | |
PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER |
|
29,706 | 2015-08-20 | 0 |
|
No longer subject to file | 2013-12-04 | 0 | |
|
No longer subject to file | 2013-12-04 | 0 | |
GORMAN GERARD G SVP, FIN. , AND CFO |
|
0 | 2013-08-16 | 0 |
|
9,167 | 2011-12-07 | 0 | |
|
6,667 | 2009-12-02 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |